These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22357809)

  • 21. Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.
    Grant PM; Tierney C; Budhathoki C; Daar ES; Sax PE; Collier AC; Fischl MA; Zolopa AR; Balamane M; Katzenstein D
    HIV Clin Trials; 2013; 14(6):284-91. PubMed ID: 24334181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
    Tan DH; Chan K; Raboud J; Cooper C; Montaner JS; Walmsley S; Hogg RS; Klein MB; Machouf N; Rourke SB; Tsoukas C; Loutfy MR;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):38-46. PubMed ID: 21709570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
    Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. WITHDRAWN: Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.
    Omeje I; Okwundu CI
    Cochrane Database Syst Rev; 2012 May; 2012(5):CD007276. PubMed ID: 22592718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.
    Omeje I; Okwundu CI
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007276. PubMed ID: 22336829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT).
    Arasteh K; Weitner L; Fenske S; Kuhlmann B; Freiwald M; Ebrahimi R; Gallo L; Ranneberg R; Mertenskoetter T
    Eur J Med Res; 2009 May; 14(5):195-9. PubMed ID: 19541575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
    Clumeck N; Mwamba C; Kabeya K; Matanda S; Vaira D; Necsoi C; Kadiebwe D; Delforge M; Kasamba E; Milolo C; Ilunga J; Kapend L
    AIDS; 2014 May; 28(8):1143-53. PubMed ID: 25028911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
    Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
    J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
    Nishijima T; Takano M; Ishisaka M; Komatsu H; Gatanaga H; Kikuchi Y; Endo T; Horiba M; Kaneda S; Uchiumi H; Koibuchi T; Naito T; Yoshida M; Tachikawa N; Ueda M; Yokomaku Y; Fujii T; Higasa S; Takada K; Yamamoto M; Matsushita S; Tateyama M; Tanabe Y; Mitsuya H; Oka S;
    Intern Med; 2013; 52(7):735-44. PubMed ID: 23545667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.
    Maitland D; Moyle G; Hand J; Mandalia S; Boffito M; Nelson M; Gazzard B
    AIDS; 2005 Jul; 19(11):1183-8. PubMed ID: 15990571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EFV/FTC/TDF-associated hepatotoxicity: a case report and review.
    Echenique IA; Rich JD
    AIDS Patient Care STDS; 2013 Sep; 27(9):493-7. PubMed ID: 23937548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.
    Ouattara E; Danel C; Moh R; Gabillard D; Peytavin G; Konan R; Carrou JL; Bohoussou F; Eholie SP; Anglaret X
    J Int AIDS Soc; 2013 Apr; 16(1):18059. PubMed ID: 23639243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
    Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
    J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1.
    Long-Term Virological Suppression Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord
    AIDS; 2019 Mar; 33(4):745-751. PubMed ID: 30829745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people.
    Bangsberg DR; Ragland K; Monk A; Deeks SG
    AIDS; 2010 Nov; 24(18):2835-40. PubMed ID: 21045636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
    HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
    Svicher V; Alteri C; Artese A; Forbici F; Santoro MM; Schols D; Van Laethem K; Alcaro S; Costa G; Tommasi C; Zaccarelli M; Narciso P; Antinori A; Ceccherini-Silberstein F; Balzarini J; Perno CF
    J Acquir Immune Defic Syndr; 2010 Nov; 55(3):336-44. PubMed ID: 20739898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.